Mezlocillin
From Wikipedia, the free encyclopedia
|
Mezlocillin
|
|
| Systematic (IUPAC) name | |
| (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl- 2-oxo-imidazolidine-1-carbonyl)amino]-2-phenyl-acetyl] amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2- carboxylic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H25N5O8S2 |
| Mol. mass | 539.584 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 16–59% |
| Metabolism | Hepatic (20–30%) |
| Half life | 1.3–4.4 hours |
| Excretion | Renal (50%) and biliary |
| Therapeutic considerations | |
| Pregnancy cat. |
B |
| Legal status | |
| Routes | Intravenous, intramuscular |
Mezlocillin is a broad-spectrum penicillin antibiotic. It is active against both Gram-negative and some Gram-positive bacteria.
Contents |
[edit] Mechanism of action
Like all other beta-lactam antibiotics, mezlocillin inhibits the third and last stage of bacterial cell wall synthesis by binding to penicillin binding proteins. This ultimately leads to cell lysis.
[edit] Susceptible organisms
[edit] Gram-negative
- Bacteroides spp., including B. fragilis
- Enterobacter spp.
- Escherichia coli
- Haemophilus influenzae
- Klebsiella species
- Morganella morganii
- Neisseria gonorrhoeae
- Proteus mirabilis
- Proteus vulgaris
- Providencia rettgeri
- Pseudomonas spp., including P. aeruginosa
- Serratia marcescens
[edit] Gram-positive
- Enterococcus faecalis
- Peptococcus spp.
- Peptostreptococcus spp.
[edit] External links
- DDB 30377
- -288358398 at GPnotebook
- Duke
- Kristof R, Clusmann H, Koehler W, Fink K, Schramm J (1998). "Treatment of accidental high dose intraventricular mezlocillin application by cerebrospinal fluid exchange.". J Neurol Neurosurg Psychiatry 64 (3): 379–81. PMID 9527154.
- McCormick P, Greenslade L, Kibbler C, Chin J, Burroughs A, McIntyre N (1997). "A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients.". Hepatology 25 (4): 833–6. doi:. PMID 9096584.
- Rohde B, Werner U, Hickstein H, Ehmcke H, Drewelow B (1997). "Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure.". Eur J Clin Pharmacol 53 (2): 111–5. doi:. PMID 9403281.
|
|||||||||||

